SG Americas Securities LLC Sells 2,662 Shares of argenx SE (NASDAQ:ARGX)

SG Americas Securities LLC lowered its holdings in shares of argenx SE (NASDAQ:ARGX) by 88.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 337 shares of the company’s stock after selling 2,662 shares during the period. SG Americas Securities LLC’s holdings in argenx were worth $183,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in ARGX. J.Safra Asset Management Corp grew its stake in shares of argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after buying an additional 59 shares during the last quarter. Blue Trust Inc. boosted its holdings in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after acquiring an additional 62 shares during the period. GAMMA Investing LLC grew its position in argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after acquiring an additional 63 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in argenx in the 2nd quarter worth approximately $76,000. Finally, Toronto Dominion Bank lifted its position in argenx by 16.5% in the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after purchasing an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of argenx stock opened at $557.92 on Thursday. argenx SE has a 1 year low of $327.73 and a 1 year high of $571.97. The firm has a market cap of $33.16 billion, a price-to-earnings ratio of -98.57 and a beta of 0.63. The company has a 50-day moving average of $533.68 and a 200 day moving average of $457.45.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The business had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. During the same quarter last year, the firm earned ($1.69) earnings per share. On average, equities analysts anticipate that argenx SE will post -0.37 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on ARGX shares. HC Wainwright lifted their target price on shares of argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Truist Financial upped their price objective on shares of argenx from $480.00 to $540.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. Guggenheim reiterated a “buy” rating and set a $585.00 target price on shares of argenx in a report on Thursday, September 26th. Oppenheimer upgraded argenx from a “market perform” rating to an “outperform” rating and set a $546.00 price target on the stock in a report on Tuesday, July 23rd. Finally, Barclays upgraded argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $550.44.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.